West Pharmaceutical Services (WST) 10-Q 28 Apr 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	Apr. 15, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	1-8036
Entity Registrant Name	WEST PHARMACEUTICAL SERVICES, INC.
Entity Incorporation, State or Country Code	PA
Entity Tax Identification Number	23-1210010
Entity Address, Address Line One	530 Herman O. West Drive
Entity Address, City or Town	Exton
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19341-0645
City Area Code	610
Local Phone Number	594-2900
Title of each class	Common Stock, par value $0.25 per share
Trading Symbol	WST
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		74,075,617
Entity Central Index Key	0000105770
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net sales	$ 720	$ 670.7
Cost of goods and services sold	435.4	398.8
Gross profit	284.6	271.9
Research and development	14.6	12.2
Selling, general and administrative expenses	83.4	80.2
Other (income) expense	(3.1)	3.9
Operating profit	189.7	175.6
Interest expense	2.2	1.9
Interest income	(0.3)	(0.1)
Other nonoperating (income) expense	0	(1.1)
Income before income taxes	187.8	174.9
Income tax expense	21.2	28.7
Equity in net income of affiliated companies	(7.2)	(5)
Net income	$ 173.8	$ 151.2
Net income per share:
Basic (in dollars per share)	$ 2.34	$ 2.04
Diluted (in dollars per share)	$ 2.29	$ 1.99
Weighted average shares outstanding:
Basic (in shares)	74.4	73.9
Diluted (in shares)	76	75.8

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 173.8	$ 151.2
Other comprehensive loss, net of tax:
Foreign currency translation adjustments	(22.1)	(28.4)
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.3 and $0.2	0.9	0.6
Net loss on derivatives, net of tax of $(0.8) and $(0.7)	(1.6)	(1.8)
Other comprehensive loss, net of tax	(22.8)	(29.6)
Comprehensive income	$ 151	$ 121.6

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Defined benefit pension and other postretirement plan adjustments, tax	$ 0.3	$ 0.2
Net (loss) gain on derivatives, tax	$ (0.8)	$ (0.7)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 667.7	$ 762.6
Accounts receivable, net	498.7	489
Inventories	416.5	378.4
Other current assets	107.6	112
Total current assets	1,690.5	1,742
Property, plant and equipment	2,237	2,215
Less: accumulated depreciation and amortization	1,171.1	1,157.5
Property, plant and equipment, net	1,065.9	1,057.5
Operating lease right-of-use assets	75.6	69.3
Investments in affiliated companies	208.1	207.7
Goodwill	108.8	109.9
Intangible assets, net	21.8	23
Deferred income taxes	66.4	48.5
Pension and other postretirement benefits	17.1	16.7
Other noncurrent assets	40.5	39.2
Total Assets	3,294.7	3,313.8
Current liabilities:
Notes payable and other current debt	44.2	44.2
Accounts payable	248.2	232.2
Pension and other postretirement benefits	2.4	2.4
Accrued salaries, wages and benefits	77.5	116.3
Income taxes payable	34.7	26.3
Operating lease liabilities	9.8	9.3
Other current liabilities	168	163.4
Total current liabilities	584.8	594.1
Long-term debt	208.3	208.8
Deferred income taxes	3.3	4.9
Pension and other postretirement benefits	38.7	40.5
Operating lease liabilities	68.9	63
Deferred compensation benefits	26.3	28.9
Other long-term liabilities	38.2	38.2
Total Liabilities	968.5	978.4
Commitments and contingencies
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding	0	0
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million in 2022 and 2021; shares outstanding: 74.1 million and 74.2 million	18.8	18.8
Capital in excess of par value	219.9	249
Retained earnings	2,617.3	2,456.7
Accumulated other comprehensive loss	(182.4)	(159.6)
Treasury stock, at cost (1.2 million and 1.1 million shares)	(347.4)	(229.5)
Total Equity	2,326.2	2,335.4
Total Liabilities and Equity	$ 3,294.7	$ 3,313.8

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	3,000,000	3,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.25	$ 0.25
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	75,300,000	75,300,000
Common stock, shares outstanding (in shares)	74,100,000	74,200,000
Treasury stock, at cost (in shares)	1,200,000	1,100,000

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net income	$ 173.8	$ 151.2
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	28.7	28
Amortization	0.9	1.1
Stock-based compensation	5.5	5.9
Pension settlement charge	0.6	0.6
Contingent consideration payments in excess of acquisition-date liability	(0.4)	(0.4)
Other non-cash items, net	(7.7)	(2.8)
Changes in assets and liabilities	(50.2)	(94.9)
Net cash provided by operating activities	151.2	88.7
Cash flows from investing activities:
Capital expenditures	(65.8)	(54.7)
Other, net	(2.5)	0.2
Net cash used in investing activities	(68.3)	(54.5)
Cash flows from financing activities:
Repayments of long-term debt	(0.6)	(0.6)
Debt issuance costs	(1.1)	0
Dividend payments	(13.4)	(12.6)
Proceeds from stock-based compensation awards	6.3	5.8
Employee stock purchase plan contributions	2	1.8
Shares purchased under share repurchase program	(147.1)	(137.1)
Shares repurchased for employee tax withholdings	(18.8)	(13.7)
Net cash used in financing activities	(172.7)	(156.4)
Effect of exchange rates on cash	(5.1)	(9.6)
Net decrease in cash and cash equivalents	(94.9)	(131.8)
Cash, including cash equivalents at beginning of period	762.6	615.5
Cash, including cash equivalents at end of period	$ 667.7	$ 483.7

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation : The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three months ended March 31, 2022, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West,” the “Company,” “we,” “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “ 2021 Annual Report ”). The results of operations for any interim period are not necessarily indicative of results for the full year. West has been actively monitoring the coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continue to operate as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.

New Accounting Standards

New Accounting Standards	3 Months Ended
	Mar. 31, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Standards	New Accounting Standards Recently Adopted Standards In November 2021, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve the transparency of financial disclosures for government assistance received by business entities. The amendment requires disclosures for transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This guidance is effective for fiscal years beginning after December 15, 2021. We adopted this guidance as of January 1, 2022, on a prospective basis. The adoption did not have a material impact on our financial statements. Standards Issued Not Yet Adopted In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We have identified the contracts impacted by reference rate reform, and have executed certain amendments to replace the use of LIBOR. The Company does not expect such adoption to cause a material impact to the consolidated financial statements.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. The following table presents the approximate percentage of our net sales by market group: Three Months Ended 2022 2021 Biologics 43 % 39 % Generics 17 % 18 % Pharma 24 % 24 % Contract-Manufactured Products 16 % 19 % 100 % 100 % The following table presents the approximate percentage of our net sales by product category: Three Months Ended 2022 2021 High-Value Product Components 56 % 52 % High-Value Product Delivery Devices 5 % 5 % Standard Packaging 23 % 24 % Contract-Manufactured Products 16 % 19 % 100 % 100 % The following table presents the approximate percentage of our net sales by geographic location: Three Months Ended 2022 2021 Americas 45 % 46 % Europe, Middle East, Africa 45 % 44 % Asia Pacific 10 % 10 % 100 % 100 % Contract Assets and Liabilities The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net: ($ in millions) Contract assets, December 31, 2021 $ 14.6 Contract assets, March 31, 2022 14.8 Change in contract assets - increase (decrease) $ 0.2 Deferred income, December 31, 2021 $ (61.3) Deferred income, March 31, 2022 (56.8) Change in deferred income - decrease (increase) $ 4.5 During the three months ended March 31, 2022, $9.7 million of revenue was recognized that was included in deferred income at the beginning of the year. The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose ® technology platform within a specific therapeutic area. As of March 31, 2022, there was $3.7 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $2.8 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.

Net Income Per Share

Net Income Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share: Three Months Ended (in millions) 2022 2021 Net income $ 173.8 $ 151.2 Weighted average common shares outstanding 74.4 73.9 Dilutive effect of equity awards, based on the treasury stock method 1.6 1.9 Weighted average shares assuming dilution 76.0 75.8 During the three months ended March 31, 2022 and 2021, there were 0.0 million and 0.1 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. In December 2021, our Board of Directors approved a share repurchase program for calendar-year 2022 authorizing the repurchase of up to 650,000 shares of our common stock from time to time on the open market as permitted under Exchange Act Rule 10b-18 or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2022. During the three months ended March 31, 2022, we purchased 390,000 shares of our common stock under the program at a cost of $147.1 million, or an average price of $377.23 per share.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows: ($ in millions) March 31, December 31, Raw materials $ 167.4 $ 153.8 Work in process 70.2 63.5 Finished goods 178.9 161.1 $ 416.5 $ 378.4

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Leases A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise. The components of lease expense were as follows: Three Months Ended ($ in millions) 2022 2021 Operating lease cost $ 3.3 $ 3.1 Short-term lease cost 0.4 0.2 Variable lease cost 1.4 0.8 Total lease cost $ 5.1 $ 4.1 Supplemental cash flow information related to leases was as follows: Three Months Ended ($ in millions) 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 3.2 $ 3.2 Right-of-use assets obtained in exchange for new operating lease liabilities $ 9.7 $ 0.5 As of March 31, 2022 and December 31, 2021, the weighted average remaining lease term for operating leases was 10.4 years and 10.7 years, respectively. As of March 31, 2022 and December 31, 2021, the weighted average discount rate was 3.52% and 3.58%, respectively. Maturities of operating lease liabilities were as follows: ($ in millions) March 31, December 31, Year 2022 2021 2022 (remaining period as of) $ 9.3 $ 11.5 2023 11.7 10.7 2024 11.1 10.0 2025 9.4 8.2 2026 8.4 7.3 Thereafter 43.8 38.7 93.7 86.4 Less: imputed lease interest (15.0) (14.1) Total lease liabilities $ 78.7 $ 72.3

Affiliated Companies

Affiliated Companies	3 Months Ended
	Mar. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Affiliated Companies	Affiliated Companies At March 31, 2022 and December 31, 2021, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $198.0 million and $201.2 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $10.1 million and $6.5 million at March 31, 2022 and December 31, 2021, respectively. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. Our purchases from, and royalty payments made to, affiliates totaled $58.5 million for the three months ended March 31, 2022, as compared to $38.0 million for the same period in 2021. As of March 31, 2022 and December 31, 2021, the payable balance due to affiliates was $45.1 million and $25.5 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products. Sales to affiliates were $4.0 million for the three months ended March 31, 2022, as compared to $2.9 million for the same period in 2021. As of March 31, 2022 and December 31, 2021, the receivable balance due from affiliates was $3.3 million and $2.3 million, respectively. Please refer to Note 7, Affiliated Companies , to the consolidated financial statements in our 2021 Annual Report for additional details.

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	Debt The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of March 31, 2022. ($ in millions) March 31, December 31, Term Loan, due December 31, 2024 (1.63%) $ 84.9 $ 85.5 Series A notes, due July 5, 2022 (3.67%) 42.0 42.0 Series B notes, due July 5, 2024 (3.82%) 53.0 53.0 Series C notes, due July 5, 2027 (4.02%) 73.0 73.0 252.9 253.5 Less: unamortized debt issuance costs 0.4 0.5 Total debt 252.5 253.0 Less: current portion of long-term debt 44.2 44.2 Long-term debt, net $ 208.3 $ 208.8 Credit Facility In March 2022, we amended and extended the existing credit facility (entered into in March 2019), which was scheduled to expire in March 2024, from $300.0 million to a $500.0 million senior unsecured revolving credit facility by entering into a Second Amendment and Joinder and Assumption Agreement (the "Amended Credit Agreement"), filed on Form 8-K dated March 31, 2022. The Amended Credit Agreement, which expires March 2027, contains a senior unsecured, multi-currency revolving credit facility of $500.0 million, with sublimits of up to $50.0 million for swing line loans for Domestic Borrowers in U.S. dollars and a $40.0 million swing line loan for West Pharmaceuticals Services Holding GmbH and up to $50.0 million for the issuance of standby letters of credit. The credit facility may be increased from time-to-time by the greater of (a) $929.0 million or (b) EBITDA for the preceding twelve month period in the aggregate through an increase in the revolving credit facility, subject to the satisfaction of certain conditions. Borrowings under the credit facility bear interest, at the Company’s option, at either: (a) the Term Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus an applicable margin; or (b) a base rate defined as the highest of: (i) the Bank of America “prime rate”; (ii) the Federal Funds effective rate plus 0.50%; and (iii) Term SOFR plus 1.00%. The applicable margin is based on the ratio of the Company’s Net Consolidated Debt to its modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for Term SOFR loans. The Amended Credit Agreement contains financial covenants providing that the Company shall not permit the ratio of the Company’s Net Consolidated Debt to its Modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Amended Credit Agreement, upon the occurrence of a Qualified Acquisition for each of the four fiscal quarters of the Company immediately following such Qualified Acquisition, the ratio set forth above shall be increased to 4.0 to 1. The Amended Credit Agreement also contains customary limitations on liens securing indebtedness of the Company and its subsidiaries, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions. At March 31, 2022, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million. Term Loan At March 31, 2022, we had $84.9 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $82.7 million was classified as long-term. Please refer to Note 9, Derivative Financial Instruments , for a discussion of the foreign currency hedge associated with the Term Loan. Please refer to Note 10, Debt , to the consolidated financial statements in our 2021 Annual Report for additional details regarding our debt agreements.

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Derivative Financial Instruments Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value. Foreign Exchange Rate Risk We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both March 31, 2022 and December 31, 2021, the total amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million. In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of March 31, 2022, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows: (in millions) Sell Currency Purchase USD EUR USD 14.4 — 12.1 JPY 5,386.8 20.0 24.2 SGD 8.3 5.6 0.6 In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. As of March 31, 2022, the notional amount of the cross-currency swap was ¥9.3 billion ($84.9 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (“Yen”) Tokyo Overnight Average Rate ("TONAR") plus a margin. Commodity Price Risk Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception. From November 2017 through March 2022, we purchased several series of call options for a total of 640,267 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases. As of March 31, 2022, we had outstanding contracts to purchase 154,320 barrels of crude oil from March 2022 to June 2023, at a weighted-average strike price of $76.06 per barrel. Effects of Derivative Instruments on Financial Position and Results of Operations Please refer to Note 10, Fair Value Measurements , for the balance sheet location and fair values of our derivative instruments as of March 31, 2022 and December 31, 2021. The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income: Amount of Gain (Loss) Recognized in Income for the Three Months Ended Location on Statement of Income ($ in millions) 2022 2021 Fair Value Hedges: Hedged item (intercompany loan) $ (9.6) $ (9.9) Other (income) expense Derivative designated as hedging instrument 9.6 9.9 Other (income) expense Amount excluded from effectiveness testing 0.8 0.6 Other (income) expense Total $ 0.8 $ 0.6 We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three months ended March 31, 2022 and 2021 were $0.8 million and $0.6 million, respectively. The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax: Amount of (Loss) Gain Recognized in OCI for the Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Location of (Gain) Loss Reclassified from Accumulated OCI into Income Three Months Ended Three Months Ended ($ in millions) 2022 2021 2022 2021 Fair Value Hedges: Foreign currency hedge contracts $ (1.2) $ (0.6) $ — $ 0.4 Other (income) expense Total $ (1.2) $ (0.6) $ — $ 0.4 Cash Flow Hedges: Foreign currency hedge contracts $ 0.4 $ (0.1) $ (0.3) $ 0.3 Net sales Foreign currency hedge contracts (1.1) (1.9) 0.5 — Cost of goods and services sold Forward treasury locks — — 0.1 0.1 Interest expense Total $ (0.7) $ (2.0) $ 0.3 $ 0.4 Net Investment Hedges: Cross-currency swap $ 3.3 $ 5.0 $ — $ — Other (income) expense Total $ 3.3 $ 5.0 $ — $ — The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income: Three Months Ended ($ in millions) 2022 2021 Net sales $ (0.3) $ 0.3 Cost of goods and services sold 0.5 — Interest expense 0.1 0.1 Other (income) expense — 0.4 The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income: Amount of Gain (Loss) Recognized in Income for the Three Months Ended Location on Statement of Income ($ in millions) 2022 2021 Commodity call options $ 2.8 $ (0.5) Other (income) expense Total $ 2.8 $ (0.5) For the three months ended March 31, 2022 and 2021, there was no material ineffectiveness related to our hedges.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels: • Level 1 : Unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2 : Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3 : Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables present the assets and liabilities recorded at fair value on a recurring basis: Balance at Basis of Fair Value Measurements ($ in millions) March 31, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 15.0 $ 15.0 $ — $ — Foreign currency contracts 23.3 — 23.3 — Cross-currency swap 8.7 — 8.7 — Commodity call options 3.9 — 3.9 — $ 50.9 $ 15.0 $ 35.9 $ — Liabilities: Contingent consideration $ 4.0 $ — $ — $ 4.0 Deferred compensation liabilities 15.4 15.4 — — Foreign currency contracts 4.5 — 4.5 — $ 23.9 $ 15.4 $ 4.5 $ 4.0 Balance at Basis of Fair Value Measurements ($ in millions) December 31, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 15.5 $ 15.5 $ — $ — Foreign currency contracts 14.8 — 14.8 — Cross-currency swap 4.4 — 4.4 — Commodity call options 1.7 — 1.7 — $ 36.4 $ 15.5 $ 20.9 $ — Liabilities: Contingent consideration $ 3.7 $ — $ — $ 3.7 Deferred compensation liabilities 16.1 16.1 — — Foreign currency contracts 3.4 — 3.4 — $ 23.2 $ 16.1 $ 3.4 $ 3.7 Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments , for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose ® technology platform (the “SmartDose ® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other (income) expense in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. Other Financial Instruments We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities. The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At March 31, 2022, the estimated fair value of long-term debt was $210.4 million compared to a carrying amount of $208.3 million. At December 31, 2021, the estimated fair value of long-term debt was $217.9 million and the carrying amount was $208.8 million.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March 31, 2022: ($ in millions) (Losses) gains on Change in equity affiliate investment AOCI Defined benefit Foreign Total Balance, December 31, 2021 $ (1.2) $ 1.5 $ (31.8) $ (128.1) $ (159.6) Other comprehensive (loss) income before reclassifications (1.9) — 0.4 (22.1) (23.6) Amounts reclassified out from accumulated other comprehensive (loss) income 0.3 — 0.5 — 0.8 Other comprehensive (loss) income, net of tax (1.6) — 0.9 (22.1) (22.8) Balance, March 31, 2022 $ (2.8) $ 1.5 $ (30.9) $ (150.2) $ (182.4) The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March 31, 2021: ($ in millions) (Losses) gains on Change in equity affiliate investment AOCI Defined benefit Foreign Total Balance, December 31, 2020 $ (1.9) $ 0.6 $ (40.5) $ (68.8) $ (110.6) Other comprehensive (loss) income before reclassifications (2.6) — 0.1 (28.4) (30.9) Amounts reclassified out from accumulated other comprehensive (loss) income 0.8 — 0.5 — 1.3 Other comprehensive (loss) income, net of tax (1.8) — 0.6 (28.4) (29.6) Balance, March 31, 2021 $ (3.7) $ 0.6 $ (39.9) $ (97.2) $ (140.2) A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: ($ in millions) Three Months Ended Location on Statement of Income Detail of components 2022 2021 (Losses) gains on derivatives: Foreign currency contracts $ 0.3 $ (0.3) Net sales Foreign currency contracts (0.5) — Cost of goods and services sold Foreign currency contracts — (0.6) Other (income) expense Forward treasury locks (0.1) (0.1) Interest expense Total before tax (0.3) (1.0) Tax benefit — 0.2 Net of tax $ (0.3) $ (0.8) Amortization of defined benefit pension and other postretirement plans: Prior service credit $ — $ 0.1 (a) Actuarial losses — (0.1) (a) Settlements (0.6) (0.6) (a) Total before tax (0.6) (0.6) Tax benefit 0.1 0.1 Net of tax $ (0.5) $ (0.5) Total reclassifications for the period, net of tax $ (0.8) $ (1.3) (a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans , for additional details.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Shareholders' Equity	Shareholders ’ Equity The following table presents the changes in shareholders’ equity for the three months ended March 31, 2022: Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total (in millions) Balance, December 31, 2021 75.3 $ 18.8 $ 249.0 1.1 $ (229.5) $ 2,456.7 $ (159.6) $ 2,335.4 Net income — — — — — 173.8 — 173.8 Activity related to stock-based compensation — — (29.1) (0.3) 29.2 — — 0.1 Shares purchased under share repurchase program — — — 0.4 (147.1) — — (147.1) Dividends declared ($0.18 per share) — — — — — (13.2) — (13.2) Other comprehensive loss, net of tax — — — — — — (22.8) (22.8) Balance, March 31, 2022 75.3 $ 18.8 $ 219.9 1.2 $ (347.4) $ 2,617.3 $ (182.4) $ 2,326.2 The following table presents the changes in shareholders’ equity for the three months ended March 31, 2021: Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total (in millions) Balance, December 31, 2020 75.3 $ 18.8 $ 267.3 1.3 $ (167.7) $ 1,846.7 $ (110.6) $ 1,854.5 Net income — — — — — 151.2 — 151.2 Activity related to stock-based compensation — — (20.6) (0.3) 23.1 — — 2.5 Shares purchased under share repurchase program — — — 0.5 (137.1) — — (137.1) Dividends declared ($0.17 per share) — — — — — (12.5) — (12.5) Other comprehensive loss, net of tax — — — — — — (29.6) (29.6) Balance, March 31, 2021 75.3 $ 18.8 $ 246.7 1.5 $ (281.7) $ 1,985.4 $ (140.2) $ 1,829.0

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At March 31, 2022, there were 1,727,432 shares remaining in the 2016 Plan for future grants. During the three months ended March 31, 2022, we granted 109,496 stock options at a weighted average exercise price of $369.13 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $96.50 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 1.8%; expected life of 5.6 years based on prior experience; stock volatility of 24.9% based on historical data; and a dividend yield of 0.2%. Stock option expense is recognized over the vesting period, net of forfeitures. During the three months ended March 31, 2022, we granted 28,688 stock-settled performance share unit ("PSU") awards at a weighted average grant-date fair value of $369.13 per share to eligible employees. These awards are earned based on the Company's performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain numbers of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee's targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. During the three months ended March 31, 2022, we granted 3,427 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $369.13 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.

Benefit Plans

Benefit Plans	3 Months Ended
	Mar. 31, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Benefit Plans	Benefit Plans The components of net periodic benefit cost for the three months ended March 31 were as follows: Pension benefits Other retirement benefits Total ($ in millions) 2022 2021 2022 2021 2022 2021 Service cost $ 0.4 $ 0.4 $ — $ — $ 0.4 $ 0.4 Interest cost 1.6 1.4 — 0.1 1.6 1.5 Expected return on assets (2.2) (3.1) — — (2.2) (3.1) Amortization of prior service credit — — — (0.1) — (0.1) Recognized actuarial losses (gains) 0.4 0.5 (0.4) (0.4) — 0.1 Settlements 0.6 0.6 — — 0.6 0.6 Net periodic benefit cost $ 0.8 $ (0.2) $ (0.4) $ (0.4) $ 0.4 $ (0.6) Pension benefits Other retirement benefits Total ($ in millions) 2022 2021 2022 2021 2022 2021 U.S. plans $ 0.4 $ (0.6) $ (0.4) $ (0.4) $ — $ (1.0) International plans 0.4 0.4 — — 0.4 0.4 Net periodic benefit cost $ 0.8 $ (0.2) $ (0.4) $ (0.4) $ 0.4 $ (0.6) During the three months ended March 31, 2022 and 2021, we recorded a pension settlement charge of $0.6 million and $0.6 million, respectively, within other nonoperating (income) expense, as we determined that normal-course lump-sum payments for our U.S. qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.

Other (Income) Expense

Other (Income) Expense	3 Months Ended
	Mar. 31, 2022
Other Income and Expenses [Abstract]
Other (Income) Expense	Other (Income) Expense Other (income) expense consists of: Three Months Ended ($ in millions) 2022 2021 Restructuring and related charges $ — $ 1.2 Fixed asset impairments and (gain) loss on sale of equipment (0.1) 0.1 Contingent consideration 0.8 0.7 Foreign exchange transaction gains (1.1) (0.3) Other items (2.7) 2.2 Total other (income) expense $ (3.1) $ 3.9 Restructuring and Related Charges In July 2020, our Board of Directors approved a restructuring plan designed to optimize certain organizational structures within the Company to better support our continued growth and business priorities. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require charges to be approximately $7 million to $8 million, with annualized savings in the range of $0.9 million to $1.6 million. Since its approval, we recorded a net pre-tax amount equal to $6.8 million in restructuring and related charges associated with this plan. The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan: ($ in millions) Severance Other charges Total Balance, December 31, 2021 $ 2.8 $ 0.5 $ 3.3 Charges — — — Cash payments (0.3) (0.1) (0.4) Balance, March 31, 2022 $ 2.5 $ 0.4 $ 2.9 Contingent Consideration Contingent consideration represents changes in the fair value of the SmartDose ® contingent consideration. Please refer to Note 10, Fair Value Measurements , for additional details. Other Items During the three months ended March 31, 2022 and 2021, we recorded a gain of $2.8 million and a loss of $0.5 million, respectively, related to oil hedges. Please refer to Note 9, Derivative Financial Instruments , for further discussion of our hedging activity.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items. The provision for income taxes was $21.2 million and $28.7 million for the three months ended March 31, 2022 and 2021, respectively, and the effective tax rate was 11.3% and 16.4%, respectively. During the three months ended March 31, 2022 and 2021, we recorded a tax benefit of $8.9 million and $11.1 million, respectively, associated with stock-based compensation. The decrease in the effective tax rate is primarily due to a $5.9 million tax benefit recorded as a result of a state tax valuation allowance reversal for the three months ended March 31, 2022, as compared to the same period in 2021.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity. There have been no significant changes to the commitments and contingencies included in our 2021 Annual Report .

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	Segment Information Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position. The following table presents information about our reportable segments, reconciled to consolidated totals: Three Months Ended ( $ in millions) 2022 2021 Net sales: Proprietary Products $ 601.3 $ 543.7 Contract-Manufactured Products 118.7 127.1 Intersegment sales elimination — (0.1) Consolidated net sales $ 720.0 $ 670.7 The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments. The following table provides summarized financial information for our segments: Three Months Ended ($ in millions) 2022 2021 Proprietary Products $ 193.4 $ 182.6 Contract-Manufactured Products 19.1 16.4 Total business segment operating profit $ 212.5 $ 199.0 Corporate and Unallocated Stock-based compensation expense $ (5.5) $ (5.9) Corporate general costs (1) (17.1) (13.9) Unallocated Items: Restructuring and related charges — (1.2) Amortization of acquisition-related intangible assets (2) (0.2) (0.2) Cost investment impairment — (2.2) Total Corporate and Unallocated (22.8) (23.4) Total consolidated operating profit $ 189.7 $ 175.6 Other expense, net 1.9 0.7 Income before income taxes $ 187.8 $ 174.9 (1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. (2) During the three months ended March 31, 2022 and 2021, we recorded $0.2 million of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. Please refer to Note 15, Other (Income) Expense , for further discussion of certain unallocated items referenced above.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	asis of Presentation : The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three months ended March 31, 2022, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West,” the “Company,” “we,” “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “ 2021 Annual Report ”). The results of operations for any interim period are not necessarily indicative of results for the full year.
Recently Adopted Standards and Standards Issued Not Yet Adopted	Recently Adopted Standards In November 2021, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve the transparency of financial disclosures for government assistance received by business entities. The amendment requires disclosures for transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This guidance is effective for fiscal years beginning after December 15, 2021. We adopted this guidance as of January 1, 2022, on a prospective basis. The adoption did not have a material impact on our financial statements. Standards Issued Not Yet Adopted In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We have identified the contracts impacted by reference rate reform, and have executed certain amendments to replace the use of LIBOR. The Company does not expect such adoption to cause a material impact to the consolidated financial statements.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table presents the approximate percentage of our net sales by market group: Three Months Ended 2022 2021 Biologics 43 % 39 % Generics 17 % 18 % Pharma 24 % 24 % Contract-Manufactured Products 16 % 19 % 100 % 100 % The following table presents the approximate percentage of our net sales by product category: Three Months Ended 2022 2021 High-Value Product Components 56 % 52 % High-Value Product Delivery Devices 5 % 5 % Standard Packaging 23 % 24 % Contract-Manufactured Products 16 % 19 % 100 % 100 % The following table presents the approximate percentage of our net sales by geographic location: Three Months Ended 2022 2021 Americas 45 % 46 % Europe, Middle East, Africa 45 % 44 % Asia Pacific 10 % 10 % 100 % 100 %
Schedule of Change in Contract With Customer, Asset and Liability	The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net: ($ in millions) Contract assets, December 31, 2021 $ 14.6 Contract assets, March 31, 2022 14.8 Change in contract assets - increase (decrease) $ 0.2 Deferred income, December 31, 2021 $ (61.3) Deferred income, March 31, 2022 (56.8) Change in deferred income - decrease (increase) $ 4.5

Net Income Per Share (Tables)

Net Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Reconciliation of Basic to Diluted Net Income Per Share	The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share: Three Months Ended (in millions) 2022 2021 Net income $ 173.8 $ 151.2 Weighted average common shares outstanding 74.4 73.9 Dilutive effect of equity awards, based on the treasury stock method 1.6 1.9 Weighted average shares assuming dilution 76.0 75.8

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows: ($ in millions) March 31, December 31, Raw materials $ 167.4 $ 153.8 Work in process 70.2 63.5 Finished goods 178.9 161.1 $ 416.5 $ 378.4

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of Lease, Cost	The components of lease expense were as follows: Three Months Ended ($ in millions) 2022 2021 Operating lease cost $ 3.3 $ 3.1 Short-term lease cost 0.4 0.2 Variable lease cost 1.4 0.8 Total lease cost $ 5.1 $ 4.1
Schedule of Cash Flow and Supplemental Information	Supplemental cash flow information related to leases was as follows: Three Months Ended ($ in millions) 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 3.2 $ 3.2 Right-of-use assets obtained in exchange for new operating lease liabilities $ 9.7 $ 0.5
Schedule of Lessee, Operating Lease, Liability, Maturity	Maturities of operating lease liabilities were as follows: ($ in millions) March 31, December 31, Year 2022 2021 2022 (remaining period as of) $ 9.3 $ 11.5 2023 11.7 10.7 2024 11.1 10.0 2025 9.4 8.2 2026 8.4 7.3 Thereafter 43.8 38.7 93.7 86.4 Less: imputed lease interest (15.0) (14.1) Total lease liabilities $ 78.7 $ 72.3

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt Obligations, Net of Current Maturities	The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of March 31, 2022. ($ in millions) March 31, December 31, Term Loan, due December 31, 2024 (1.63%) $ 84.9 $ 85.5 Series A notes, due July 5, 2022 (3.67%) 42.0 42.0 Series B notes, due July 5, 2024 (3.82%) 53.0 53.0 Series C notes, due July 5, 2027 (4.02%) 73.0 73.0 252.9 253.5 Less: unamortized debt issuance costs 0.4 0.5 Total debt 252.5 253.0 Less: current portion of long-term debt 44.2 44.2 Long-term debt, net $ 208.3 $ 208.8

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Foreign Currency Contracts	As of March 31, 2022, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows: (in millions) Sell Currency Purchase USD EUR USD 14.4 — 12.1 JPY 5,386.8 20.0 24.2 SGD 8.3 5.6 0.6
Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings	The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income: Amount of Gain (Loss) Recognized in Income for the Three Months Ended Location on Statement of Income ($ in millions) 2022 2021 Fair Value Hedges: Hedged item (intercompany loan) $ (9.6) $ (9.9) Other (income) expense Derivative designated as hedging instrument 9.6 9.9 Other (income) expense Amount excluded from effectiveness testing 0.8 0.6 Other (income) expense Total $ 0.8 $ 0.6 The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax: Amount of (Loss) Gain Recognized in OCI for the Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Location of (Gain) Loss Reclassified from Accumulated OCI into Income Three Months Ended Three Months Ended ($ in millions) 2022 2021 2022 2021 Fair Value Hedges: Foreign currency hedge contracts $ (1.2) $ (0.6) $ — $ 0.4 Other (income) expense Total $ (1.2) $ (0.6) $ — $ 0.4 Cash Flow Hedges: Foreign currency hedge contracts $ 0.4 $ (0.1) $ (0.3) $ 0.3 Net sales Foreign currency hedge contracts (1.1) (1.9) 0.5 — Cost of goods and services sold Forward treasury locks — — 0.1 0.1 Interest expense Total $ (0.7) $ (2.0) $ 0.3 $ 0.4 Net Investment Hedges: Cross-currency swap $ 3.3 $ 5.0 $ — $ — Other (income) expense Total $ 3.3 $ 5.0 $ — $ — The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income: Three Months Ended ($ in millions) 2022 2021 Net sales $ (0.3) $ 0.3 Cost of goods and services sold 0.5 — Interest expense 0.1 0.1 Other (income) expense — 0.4
Schedule of Derivatives Not Designated as Hedging Instruments	The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income: Amount of Gain (Loss) Recognized in Income for the Three Months Ended Location on Statement of Income ($ in millions) 2022 2021 Commodity call options $ 2.8 $ (0.5) Other (income) expense Total $ 2.8 $ (0.5)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value	The following tables present the assets and liabilities recorded at fair value on a recurring basis: Balance at Basis of Fair Value Measurements ($ in millions) March 31, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 15.0 $ 15.0 $ — $ — Foreign currency contracts 23.3 — 23.3 — Cross-currency swap 8.7 — 8.7 — Commodity call options 3.9 — 3.9 — $ 50.9 $ 15.0 $ 35.9 $ — Liabilities: Contingent consideration $ 4.0 $ — $ — $ 4.0 Deferred compensation liabilities 15.4 15.4 — — Foreign currency contracts 4.5 — 4.5 — $ 23.9 $ 15.4 $ 4.5 $ 4.0 Balance at Basis of Fair Value Measurements ($ in millions) December 31, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 15.5 $ 15.5 $ — $ — Foreign currency contracts 14.8 — 14.8 — Cross-currency swap 4.4 — 4.4 — Commodity call options 1.7 — 1.7 — $ 36.4 $ 15.5 $ 20.9 $ — Liabilities: Contingent consideration $ 3.7 $ — $ — $ 3.7 Deferred compensation liabilities 16.1 16.1 — — Foreign currency contracts 3.4 — 3.4 — $ 23.2 $ 16.1 $ 3.4 $ 3.7

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of Components of Accumulated Other Comprehensive Loss	The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March 31, 2022: ($ in millions) (Losses) gains on Change in equity affiliate investment AOCI Defined benefit Foreign Total Balance, December 31, 2021 $ (1.2) $ 1.5 $ (31.8) $ (128.1) $ (159.6) Other comprehensive (loss) income before reclassifications (1.9) — 0.4 (22.1) (23.6) Amounts reclassified out from accumulated other comprehensive (loss) income 0.3 — 0.5 — 0.8 Other comprehensive (loss) income, net of tax (1.6) — 0.9 (22.1) (22.8) Balance, March 31, 2022 $ (2.8) $ 1.5 $ (30.9) $ (150.2) $ (182.4) The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March 31, 2021: ($ in millions) (Losses) gains on Change in equity affiliate investment AOCI Defined benefit Foreign Total Balance, December 31, 2020 $ (1.9) $ 0.6 $ (40.5) $ (68.8) $ (110.6) Other comprehensive (loss) income before reclassifications (2.6) — 0.1 (28.4) (30.9) Amounts reclassified out from accumulated other comprehensive (loss) income 0.8 — 0.5 — 1.3 Other comprehensive (loss) income, net of tax (1.8) — 0.6 (28.4) (29.6) Balance, March 31, 2021 $ (3.7) $ 0.6 $ (39.9) $ (97.2) $ (140.2)
Schedule of Reclassification out of Accumulated Other Comprehensive Loss	A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: ($ in millions) Three Months Ended Location on Statement of Income Detail of components 2022 2021 (Losses) gains on derivatives: Foreign currency contracts $ 0.3 $ (0.3) Net sales Foreign currency contracts (0.5) — Cost of goods and services sold Foreign currency contracts — (0.6) Other (income) expense Forward treasury locks (0.1) (0.1) Interest expense Total before tax (0.3) (1.0) Tax benefit — 0.2 Net of tax $ (0.3) $ (0.8) Amortization of defined benefit pension and other postretirement plans: Prior service credit $ — $ 0.1 (a) Actuarial losses — (0.1) (a) Settlements (0.6) (0.6) (a) Total before tax (0.6) (0.6) Tax benefit 0.1 0.1 Net of tax $ (0.5) $ (0.5) Total reclassifications for the period, net of tax $ (0.8) $ (1.3) (a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans , for additional details.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of Stockholders Equity	The following table presents the changes in shareholders’ equity for the three months ended March 31, 2022: Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total (in millions) Balance, December 31, 2021 75.3 $ 18.8 $ 249.0 1.1 $ (229.5) $ 2,456.7 $ (159.6) $ 2,335.4 Net income — — — — — 173.8 — 173.8 Activity related to stock-based compensation — — (29.1) (0.3) 29.2 — — 0.1 Shares purchased under share repurchase program — — — 0.4 (147.1) — — (147.1) Dividends declared ($0.18 per share) — — — — — (13.2) — (13.2) Other comprehensive loss, net of tax — — — — — — (22.8) (22.8) Balance, March 31, 2022 75.3 $ 18.8 $ 219.9 1.2 $ (347.4) $ 2,617.3 $ (182.4) $ 2,326.2 The following table presents the changes in shareholders’ equity for the three months ended March 31, 2021: Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total (in millions) Balance, December 31, 2020 75.3 $ 18.8 $ 267.3 1.3 $ (167.7) $ 1,846.7 $ (110.6) $ 1,854.5 Net income — — — — — 151.2 — 151.2 Activity related to stock-based compensation — — (20.6) (0.3) 23.1 — — 2.5 Shares purchased under share repurchase program — — — 0.5 (137.1) — — (137.1) Dividends declared ($0.17 per share) — — — — — (12.5) — (12.5) Other comprehensive loss, net of tax — — — — — — (29.6) (29.6) Balance, March 31, 2021 75.3 $ 18.8 $ 246.7 1.5 $ (281.7) $ 1,985.4 $ (140.2) $ 1,829.0

Benefit Plans (Tables)

Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Schedule of Components of Net Periodic Benefit Cost	The components of net periodic benefit cost for the three months ended March 31 were as follows: Pension benefits Other retirement benefits Total ($ in millions) 2022 2021 2022 2021 2022 2021 Service cost $ 0.4 $ 0.4 $ — $ — $ 0.4 $ 0.4 Interest cost 1.6 1.4 — 0.1 1.6 1.5 Expected return on assets (2.2) (3.1) — — (2.2) (3.1) Amortization of prior service credit — — — (0.1) — (0.1) Recognized actuarial losses (gains) 0.4 0.5 (0.4) (0.4) — 0.1 Settlements 0.6 0.6 — — 0.6 0.6 Net periodic benefit cost $ 0.8 $ (0.2) $ (0.4) $ (0.4) $ 0.4 $ (0.6) Pension benefits Other retirement benefits Total ($ in millions) 2022 2021 2022 2021 2022 2021 U.S. plans $ 0.4 $ (0.6) $ (0.4) $ (0.4) $ — $ (1.0) International plans 0.4 0.4 — — 0.4 0.4 Net periodic benefit cost $ 0.8 $ (0.2) $ (0.4) $ (0.4) $ 0.4 $ (0.6)

Other (Income) Expense (Tables)

Other (Income) Expense (Tables)	3 Months Ended
	Mar. 31, 2022
Other Income and Expenses [Abstract]
Schedule of Other Expense (Income)	Other (income) expense consists of: Three Months Ended ($ in millions) 2022 2021 Restructuring and related charges $ — $ 1.2 Fixed asset impairments and (gain) loss on sale of equipment (0.1) 0.1 Contingent consideration 0.8 0.7 Foreign exchange transaction gains (1.1) (0.3) Other items (2.7) 2.2 Total other (income) expense $ (3.1) $ 3.9
Schedule of Restructuring Reserve	The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan: ($ in millions) Severance Other charges Total Balance, December 31, 2021 $ 2.8 $ 0.5 $ 3.3 Charges — — — Cash payments (0.3) (0.1) (0.4) Balance, March 31, 2022 $ 2.5 $ 0.4 $ 2.9

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of Sales by Significant Product Group	The following table presents information about our reportable segments, reconciled to consolidated totals: Three Months Ended ( $ in millions) 2022 2021 Net sales: Proprietary Products $ 601.3 $ 543.7 Contract-Manufactured Products 118.7 127.1 Intersegment sales elimination — (0.1) Consolidated net sales $ 720.0 $ 670.7
Schedule of Segment Reporting Information, by Segment	The following table provides summarized financial information for our segments: Three Months Ended ($ in millions) 2022 2021 Proprietary Products $ 193.4 $ 182.6 Contract-Manufactured Products 19.1 16.4 Total business segment operating profit $ 212.5 $ 199.0 Corporate and Unallocated Stock-based compensation expense $ (5.5) $ (5.9) Corporate general costs (1) (17.1) (13.9) Unallocated Items: Restructuring and related charges — (1.2) Amortization of acquisition-related intangible assets (2) (0.2) (0.2) Cost investment impairment — (2.2) Total Corporate and Unallocated (22.8) (23.4) Total consolidated operating profit $ 189.7 $ 175.6 Other expense, net 1.9 0.7 Income before income taxes $ 187.8 $ 174.9 (1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. (2) During the three months ended March 31, 2022 and 2021, we recorded $0.2 million of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.

Revenue - Revenue Recognition (

Revenue - Revenue Recognition (Details) - Revenue Benchmark	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Customer Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	100.00%	100.00%
Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	100.00%	100.00%
Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	100.00%	100.00%
Americas | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	45.00%	46.00%
Europe, Middle East, Africa | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	45.00%	44.00%
Asia Pacific | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	10.00%	10.00%
High-Value Product Components | Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	56.00%	52.00%
High-Value Product Delivery Devices | Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	5.00%	5.00%
Standard Packaging | Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	23.00%	24.00%
Contract-Manufactured Products | Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	16.00%	19.00%
Biologics | Customer Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	43.00%	39.00%
Generics | Customer Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	17.00%	18.00%
Pharma | Customer Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	24.00%	24.00%
Contract-Manufactured Products | Customer Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	16.00%	19.00%

Revenue - Contracts and Liabili

Revenue - Contracts and Liabilities (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Contract With Customer, Asset [Roll Forward]
Contract assets, December 31, 2021	$ 14.6
Contract assets, March 31, 2022	14.8
Change in contract assets - increase (decrease)	0.2
Contract With Customer, Liability [Roll Forward]
Deferred income, December 31, 2021	(61.3)
Deferred income, March 31, 2022	(56.8)
Change in deferred income - decrease (increase)	$ 4.5

Revenue - Contracts and Liabi_2

Revenue - Contracts and Liabilities, Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2013
Disaggregation of Revenue [Line Items]
Revenue recognized that was included in the deferred income balance	$ 9.7
Deferred income	56.8	$ 61.3
Smart Dose
Disaggregation of Revenue [Line Items]
Deferred income	3.7		$ 20
Deferred income, current	0.9
Deferred income, noncurrent	$ 2.8

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Earnings Per Share [Abstract]
Net income	$ 173.8	$ 151.2
Weighted average common shares outstanding (in shares)	74,400,000	73,900,000
Dilutive effect of equity awards, based on the treasury stock method (in shares)	1,600,000	1,900,000
Weighted average shares assuming dilution (in shares)	76,000,000	75,800,000
Antidilutive options excluded from computation of diluted net income per share (in shares)	0	100,000
Stock repurchase program, shares authorized (in shares)			650,000
Stock repurchase program, shares purchased (in shares)	390,000
Stock purchase program, cost of shares purchased	$ 147.1	$ 137.1
Stock repurchase program, average price per share (in dollars per share)	$ 377.23

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 167.4	$ 153.8
Work in process	70.2	63.5
Finished goods	178.9	161.1
Total inventories	$ 416.5	$ 378.4

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating lease cost	$ 3.3	$ 3.1
Short-term lease cost	0.4	0.2
Variable lease cost	1.4	0.8
Total lease cost	$ 5.1	$ 4.1

Leases - Lease Cash Flow and Su

Leases - Lease Cash Flow and Supplemental Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 3.2	$ 3.2
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 9.7	$ 0.5

Leases - Lease Weighted Average

Leases - Lease Weighted Average (Details)	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted average remaining lease term	10 years 4 months 24 days	10 years 8 months 12 days
Weighted average discount rate	3.52%	3.58%

Leases - Maturities of Operatin

Leases - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Remainder of fiscal year	$ 9.3
Year one	11.7	$ 11.5
Year two	11.1	10.7
Year three	9.4	10
Year four	8.4	8.2
Year five		7.3
Thereafter	43.8
Thereafter		38.7
Operating leases liabilities payments due	93.7	86.4
Less: imputed lease interest	(15)	(14.1)
Total lease liabilities	$ 78.7	$ 72.3

Affiliated Companies (Details)

Affiliated Companies (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
Carrying amount, equity-method investments	$ 198		$ 201.2
Carrying amount, investments not accounted for under the equity method	10.1		6.5
Purchases and royalty payments made to affiliates	58.5	$ 38
Amount due and payable to affiliates	45.1		25.5
Sales to affiliates	4	$ 2.9
Amount receivable from affiliates	$ 3.3		$ 2.3

Debt - Long-term Debt (Details)

Debt - Long-term Debt (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt, gross	$ 252.9	$ 253.5
Less: unamortized debt issuance costs	0.4	0.5
Total debt	252.5	253
Less: current portion of long-term debt	44.2	44.2
Long-term debt, net	$ 208.3	208.8
Term Loan, due December 31, 2024 (1.63%)
Debt Instrument [Line Items]
Debt instrument, stated interest rate	1.63%
Long-term debt, gross	$ 84.9	85.5
Long-term debt, net	$ 82.7
Series A notes, due July 5, 2022 (3.67%)
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.67%
Long-term debt, gross	$ 42	42
Series B notes, due July 5, 2024 (3.82%)
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.82%
Long-term debt, gross	$ 53	53
Series C notes, due July 5, 2027 (4.02%)
Debt Instrument [Line Items]
Debt instrument, stated interest rate	4.02%
Long-term debt, gross	$ 73	$ 73

Debt - Credit Facility (Details

Debt - Credit Facility (Details) $ in Millions	1 Months Ended
	Mar. 31, 2022USD ($)instancefiscal_quarter	Dec. 31, 2021USD ($)
Line of Credit Facility [Line Items]
Long-term debt, gross	$ 252.9	$ 253.5
Long-term debt	$ 208.3	208.8
Base Rate | Minimum
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	0.00%
Base Rate | Maximum
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	0.375%
Revolving Credit Facility, Due 2024
Line of Credit Facility [Line Items]
Line of credit facility, current borrowing capacity	$ 500
Credit available for the issuance of letters of credit	50
Line of credit facility, additional borrowing capacity	$ 929
Preceding period	12 months
Number of instances not to exceed | instance	3
Number of quarters following acquisition | fiscal_quarter	4
Line of credit facility, unused commitment level	$ 497.6
Revolving Credit Facility, Due 2024 | Minimum
Line of Credit Facility [Line Items]
Line of credit facility, current borrowing capacity	$ 300
Ratio of debt to EBITDA	3.5
Revolving Credit Facility, Due 2024 | Maximum
Line of Credit Facility [Line Items]
Line of credit facility, current borrowing capacity	$ 500
Ratio of debt to EBITDA	4
Revolving Credit Facility, Due 2024 | Domestic Line of Credit
Line of Credit Facility [Line Items]
Credit facility is available for swing-line loans	$ 50
Revolving Credit Facility, Due 2024 | Foreign Line of Credit
Line of Credit Facility [Line Items]
Credit facility is available for swing-line loans	$ 40
Revolving Credit Facility, Due 2024 | SOFR
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	0.10%
Revolving Credit Facility, Due 2024 | Federal Funds Effective Rate Plus
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	0.50%
Revolving Credit Facility, Due 2024 | LIBOR
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	1.00%
Revolving Credit Facility, Due 2024 | LIBOR | Minimum
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	0.875%
Revolving Credit Facility, Due 2024 | LIBOR | Maximum
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	1.375%
Revolving Credit Facility, Due 2024 | Letter of Credit
Line of Credit Facility [Line Items]
Long-term line of credit	$ 2.4
Term Loan Due 2024
Line of Credit Facility [Line Items]
Long-term debt, gross	84.9	$ 85.5
Long-term debt, current	2.2
Long-term debt	$ 82.7

Derivative Financial Instrume_3

Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) € in Millions, ¥ in Millions, $ in Millions, $ in Millions	3 Months Ended	53 Months Ended
	Mar. 31, 2022SGD ($)$ / bblbbl	Mar. 31, 2022SGD ($)$ / bblbbl	Mar. 31, 2022USD ($)$ / bbl	Mar. 31, 2022EUR (€)$ / bbl	Mar. 31, 2022JPY (¥)$ / bbl	Dec. 31, 2021SGD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2019JPY (¥)
Foreign Exchange Forward
Derivative [Line Items]
Derivative contract term	18 months
Options Held
Derivative [Line Items]
Derivative, nonmonetary notional amount, volume | bbl	154,320	640,267
Derivative, average price risk option strike price | $ / bbl	76.06	76.06	76.06	76.06	76.06
USD | Forward Contracts
Derivative [Line Items]
Derivative, notional amount			$ 13.4				$ 13.4
USD | Foreign Exchange Forward | Long | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount			14.4
USD | Foreign Exchange Forward | Short | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount			0	€ 12.1
USD | Cross Currency Interest Rate Contract
Derivative [Line Items]
Derivative, notional amount								$ 84.9
USD | Cross Currency Interest Rate Contract | Net Investment Hedges
Derivative [Line Items]
Derivative, notional amount								$ 90
JPY | Foreign Exchange Forward | Long | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount | ¥					¥ 5,386.8
JPY | Foreign Exchange Forward | Short | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount			20	24.2
JPY | Cross Currency Interest Rate Contract
Derivative [Line Items]
Derivative, notional amount | ¥									¥ 9,300
SGD | Forward Contracts
Derivative [Line Items]
Derivative, notional amount	$ 601.5	$ 601.5				$ 601.5
SGD | Foreign Exchange Forward | Long | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount	$ 8.3	$ 8.3
SGD | Foreign Exchange Forward | Short | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount			$ 5.6	€ 0.6

Derivative Financial Instrume_4

Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Derivative (gain) loss recognized in income, fair value hedges	$ 0.8	$ 0.6
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	2.8	(0.5)
Fair Value Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, forward point components, gain (loss), recognized in earnings	0.8	0.6
Fair value and net investment hedges, amount of gain (loss) recognized in OCI	(1.2)	(0.6)
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income	0	0.4
Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedges, amount of gain (loss) recognized in OCI	(0.7)	(2)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.3	0.4
Net Investment Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Fair value and net investment hedges, amount of gain (loss) recognized in OCI	3.3	5
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income	0	0
Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instruments, net, pretax	(0.3)	0.3
Net sales | Cash Flow Hedges | Foreign currency hedge contracts
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedges, amount of gain (loss) recognized in OCI	0.4	(0.1)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	(0.3)	0.3
Cost of goods and services sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instruments, net, pretax	0.5	0
Cost of goods and services sold | Commodity call options | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	2.8	(0.5)
Cost of goods and services sold | Cash Flow Hedges | Foreign currency hedge contracts
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedges, amount of gain (loss) recognized in OCI	(1.1)	(1.9)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.5	0
Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instruments, net, pretax	0.1	0.1
Interest expense | Cash Flow Hedges | Forward treasury locks
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedges, amount of gain (loss) recognized in OCI	0	0
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.1	0.1
Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative (gain) loss on hedged item, fair value hedges	(9.6)	(9.9)
Change in unrealized gain (loss) on fair value hedging instruments	9.6	9.9
Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges	0.8	0.6
Gain (loss) on derivative instruments, net, pretax	0	0.4
Other (income) expense | Commodity call options | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	2.8	(0.5)
Other (income) expense | Fair Value Hedges | Foreign currency hedge contracts
Derivative Instruments, Gain (Loss) [Line Items]
Fair value and net investment hedges, amount of gain (loss) recognized in OCI	(1.2)	(0.6)
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income	0	0.4
Other (income) expense | Net Investment Hedges | Cross-currency swap
Derivative Instruments, Gain (Loss) [Line Items]
Fair value and net investment hedges, amount of gain (loss) recognized in OCI	3.3	5
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income	$ 0	$ 0

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Assets:
Deferred compensation assets	$ 15	$ 15.5
Foreign currency contracts	23.3	14.8
Total assets at fair value	50.9	36.4
Liabilities:
Contingent consideration	4	3.7
Deferred compensation liabilities	15.4	16.1
Total liabilities at fair value	23.9	23.2
Cross-currency swap
Assets:
Commodity call options	8.7	4.4
Commodity call options
Assets:
Commodity call options	3.9	1.7
Foreign currency contracts
Liabilities:
Foreign currency contracts and swaps	4.5	3.4
Level 1
Assets:
Deferred compensation assets	15	15.5
Foreign currency contracts	0	0
Total assets at fair value	15	15.5
Liabilities:
Contingent consideration	0	0
Deferred compensation liabilities	15.4	16.1
Total liabilities at fair value	15.4	16.1
Level 1 | Cross-currency swap
Assets:
Commodity call options	0	0
Level 1 | Commodity call options
Assets:
Commodity call options	0	0
Level 1 | Foreign currency contracts
Liabilities:
Foreign currency contracts and swaps	0	0
Level 2
Assets:
Deferred compensation assets	0	0
Foreign currency contracts	23.3	14.8
Total assets at fair value	35.9	20.9
Liabilities:
Contingent consideration	0	0
Deferred compensation liabilities	0	0
Total liabilities at fair value	4.5	3.4
Level 2 | Cross-currency swap
Assets:
Commodity call options	8.7	4.4
Level 2 | Commodity call options
Assets:
Commodity call options	3.9	1.7
Level 2 | Foreign currency contracts
Liabilities:
Foreign currency contracts and swaps	4.5	3.4
Level 3
Assets:
Deferred compensation assets	0	0
Foreign currency contracts	0	0
Total assets at fair value	0	0
Liabilities:
Contingent consideration	4	3.7
Deferred compensation liabilities	0	0
Total liabilities at fair value	4	3.7
Level 3 | Cross-currency swap
Assets:
Commodity call options	0	0
Level 3 | Commodity call options
Assets:
Commodity call options	0	0
Level 3 | Foreign currency contracts
Liabilities:
Foreign currency contracts and swaps	$ 0	$ 0

Fair Value Measurements - Other

Fair Value Measurements - Other Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Other Financial Instruments [Abstract]
Long-term debt, fair value	$ 210.4	$ 217.9
Long-term debt	$ 208.3	$ 208.8

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning of period	$ 2,335.4	$ 1,854.5
Other comprehensive (loss) income before reclassifications	(23.6)	(30.9)
Amounts reclassified out from accumulated other comprehensive (loss) income	0.8	1.3
Other comprehensive loss, net of tax	(22.8)	(29.6)
Balance, end of period	2,326.2	1,829
Total
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning of period	(159.6)	(110.6)
Other comprehensive loss, net of tax	(22.8)	(29.6)
Balance, end of period	(182.4)	(140.2)
(Losses) gains on derivatives
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning of period	(1.2)	(1.9)
Other comprehensive (loss) income before reclassifications	(1.9)	(2.6)
Amounts reclassified out from accumulated other comprehensive (loss) income	0.3	0.8
Other comprehensive loss, net of tax	(1.6)	(1.8)
Balance, end of period	(2.8)	(3.7)
Change in equity affiliate investment AOCI
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning of period	1.5	0.6
Other comprehensive (loss) income before reclassifications	0	0
Amounts reclassified out from accumulated other comprehensive (loss) income	0	0
Other comprehensive loss, net of tax	0	0
Balance, end of period	1.5	0.6
Defined benefit pension and other postretirement plans
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning of period	(31.8)	(40.5)
Other comprehensive (loss) income before reclassifications	0.4	0.1
Amounts reclassified out from accumulated other comprehensive (loss) income	0.5	0.5
Other comprehensive loss, net of tax	0.9	0.6
Balance, end of period	(30.9)	(39.9)
Foreign currency translation
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning of period	(128.1)	(68.8)
Other comprehensive (loss) income before reclassifications	(22.1)	(28.4)
Amounts reclassified out from accumulated other comprehensive (loss) income	0	0
Other comprehensive loss, net of tax	(22.1)	(28.4)
Balance, end of period	$ (150.2)	$ (97.2)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Net sales	$ 720	$ 670.7
Cost of goods and services sold	(435.4)	(398.8)
Interest expense	(2.2)	(1.9)
Prior service credit	0	0.1
Actuarial losses	0	(0.1)
Settlements	(0.6)	(0.6)
Income before income taxes	187.8	174.9
Tax benefit	(21.2)	(28.7)
Net income	173.8	151.2
Reclassification out of Accumulated Other Comprehensive Loss
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Net income	(0.8)	(1.3)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Income before income taxes	(0.3)	(1)
Tax benefit	0	0.2
Net income	(0.3)	(0.8)
Reclassification out of Accumulated Other Comprehensive Loss | Amortization of defined benefit pension and other postretirement plans
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Prior service credit	0	0.1
Actuarial losses	0	(0.1)
Settlements	(0.6)	(0.6)
Income before income taxes	(0.6)	(0.6)
Tax benefit	0.1	0.1
Net income	(0.5)	(0.5)
Foreign currency contracts | Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Net sales	0.3	(0.3)
Cost of goods and services sold	(0.5)	0
Other (income) expense	0	(0.6)
Forward treasury locks | Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Interest expense	$ (0.1)	$ (0.1)

Shareholders' Equity - Change i

Shareholders' Equity - Change in Shareholders' Equity (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning of period	$ 2,335.4	$ 1,854.5
Net income	173.8	151.2
Activity related to stock-based compensation	$ 0.1	2.5
Share purchased under share repurchase program (in shares)	390,000
Shares purchased under share repurchase program	$ (147.1)	(137.1)
Dividends declared	(13.2)	(12.5)
Other comprehensive loss, net of tax	(22.8)	(29.6)
Balance, end of period	$ 2,326.2	$ 1,829
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance (in shares)	75,300,000	75,300,000
Balance, beginning of period	$ 18.8	$ 18.8
Balance (in shares)	75,300,000	75,300,000
Balance, end of period	$ 18.8	$ 18.8
Capital in Excess of Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning of period	249	267.3
Activity related to stock-based compensation	(29.1)	(20.6)
Balance, end of period	$ 219.9	$ 246.7
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance (in shares)	1,100,000	1,300,000
Balance, beginning of period	$ (229.5)	$ (167.7)
Activity related to stock -based compensation (in shares)	(300,000)	(300,000)
Activity related to stock-based compensation	$ 29.2	$ 23.1
Share purchased under share repurchase program (in shares)	400,000	500,000
Shares purchased under share repurchase program	$ (147.1)	$ (137.1)
Balance (in shares)	1,200,000	1,500,000
Balance, end of period	$ (347.4)	$ (281.7)
Retained earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning of period	2,456.7	1,846.7
Net income	173.8	151.2
Dividends declared	(13.2)	(12.5)
Balance, end of period	2,617.3	1,985.4
Accumulated other comprehensive loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning of period	(159.6)	(110.6)
Other comprehensive loss, net of tax	(22.8)	(29.6)
Balance, end of period	$ (182.4)	$ (140.2)

Shareholders' Equity - Suppleme

Shareholders' Equity - Supplemental Equity Information (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Equity [Abstract]
Dividends declared per share (in dollars per share)	$ 0.18	$ 0.17

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance under the 2016 Plan (in shares)	1,727,432
Stock options, granted (in shares)	109,496
Stock options, weighted average exercise price (in dollars per share)	$ 369.13
Stock options, weighted average grant date fair value (in dollars per share)	$ 96.50
Risk-free interest rate	1.80%
Expected life	5 years 7 months 6 days
Stock volatility	24.90%
Dividend yield	0.20%
Stock-based compensation expense	$ 5.5	$ 5.9
Performance Share Unit (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	28,688
Grant date fair value (in dollars per share)	$ 369.13
Performance Share Unit (PSUs) | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target award percentage	0.00%
Performance Share Unit (PSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target award percentage	200.00%
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	3,427
Grant date fair value (in dollars per share)	$ 369.13

Benefit Plans - Schedule of Com

Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Service cost	$ 0.4	$ 0.4
Interest cost	1.6	1.5
Expected return on assets	(2.2)	(3.1)
Amortization of prior service credit	0	(0.1)
Recognized actuarial losses (gains)	0	0.1
Settlements	0.6	0.6
Net periodic benefit cost	0.4	(0.6)
U.S. plans
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	0	(1)
International plans
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	0.4	0.4
Pension benefits
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Service cost	0.4	0.4
Interest cost	1.6	1.4
Expected return on assets	(2.2)	(3.1)
Amortization of prior service credit	0	0
Recognized actuarial losses (gains)	0.4	0.5
Settlements	0.6	0.6
Net periodic benefit cost	0.8	(0.2)
Pension benefits | U.S. plans
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	0.4	(0.6)
Pension benefits | International plans
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	0.4	0.4
Other retirement benefits
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Service cost	0	0
Interest cost	0	0.1
Expected return on assets	0	0
Amortization of prior service credit	0	(0.1)
Recognized actuarial losses (gains)	(0.4)	(0.4)
Settlements	0	0
Net periodic benefit cost	(0.4)	(0.4)
Other retirement benefits | U.S. plans
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	(0.4)	(0.4)
Other retirement benefits | International plans
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	$ 0	$ 0

Benefit Plans - Narrative (Deta

Benefit Plans - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Settlements	$ 0.6	$ 0.6
Pension benefits
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Settlements	$ 0.6	$ 0.6

Other (Income) Expense - Schedu

Other (Income) Expense - Schedule of Other (Income) Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Other Income and Expenses [Abstract]
Restructuring and related charges	$ 0	$ 1.2
Fixed asset impairments and (gain) loss on sale of equipment	(0.1)	0.1
Contingent consideration	0.8	0.7
Foreign exchange transaction gains	(1.1)	(0.3)
Other items	(2.7)	2.2
Total other (income) expense	$ (3.1)	$ 3.9

Other (Income) Expense - Narrat

Other (Income) Expense - Narrative (Details) - 2020 Restructuring Plan - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jul. 31, 2020	Mar. 31, 2022
Summary of Investment Holdings [Line Items]
Restructuring and related activities, period of implementation	24 months
Restructuring and related cost, cumulative cost incurred		$ 6.8
Minimum
Summary of Investment Holdings [Line Items]
Restructuring and related cost, expected cost		7
Effect on future earnings, amount		0.9
Maximum
Summary of Investment Holdings [Line Items]
Restructuring and related cost, expected cost		8
Effect on future earnings, amount		$ 1.6

Other (Income) Expense - Sche_2

Other (Income) Expense - Schedule of Restructuring and Related Charges (Details) - 2020 Restructuring Plan $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Restructuring Reserve [Roll Forward]
Balance, December 31, 2021	$ 3.3
Charges	0
Cash payments	(0.4)
Balance, March 31, 2022	2.9
Severance and benefits
Restructuring Reserve [Roll Forward]
Balance, December 31, 2021	2.8
Charges	0
Cash payments	(0.3)
Balance, March 31, 2022	2.5
Other charges
Restructuring Reserve [Roll Forward]
Balance, December 31, 2021	0.5
Charges	0
Cash payments	(0.1)
Balance, March 31, 2022	$ 0.4

Other (Income) Expense - Other

Other (Income) Expense - Other Items (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Impairment of cost method investments		$ 2.2
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	$ 2.8	(0.5)
Commodity call options | Not Designated as Hedging Instrument | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	$ 2.8	$ (0.5)

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 21.2	$ 28.7
Effective income tax rate	11.30%	16.40%
Tax benefit associated with stock-based compensation	$ 8.9	$ 11.1
Tax benefit of state tax valuation allowance	$ 5.9

Segment Information - Narrative

Segment Information - Narrative (Details)	3 Months Ended
	Mar. 31, 2022segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Information - Sales by

Segment Information - Sales by Product Group (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	$ 720	$ 670.7
Intersegment sales elimination
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	0	(0.1)
Proprietary Products | Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	601.3	543.7
Contract-Manufactured Products | Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	$ 118.7	$ 127.1

Segment Information - Segment F

Segment Information - Segment Financial Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Operating profit	$ 189.7	$ 175.6
Stock-based compensation expense	(5.5)	(5.9)
Amortization of acquisition-related intangible assets	(0.2)	(0.2)
Other expense, net	1.9	0.7
Income before income taxes	187.8	174.9
Operating Segments
Segment Reporting Information [Line Items]
Operating profit	212.5	199
Corporate and Unallocated
Segment Reporting Information [Line Items]
Operating profit	(22.8)	(23.4)
Stock-based compensation expense	(5.5)	(5.9)
Corporate general costs	(17.1)	(13.9)
Restructuring and related charges	0	(1.2)
Amortization of acquisition-related intangible assets	(0.2)	(0.2)
Cost investment activity	0	(2.2)
Proprietary Products | Operating Segments
Segment Reporting Information [Line Items]
Operating profit	193.4	182.6
Contract-Manufactured Products | Operating Segments
Segment Reporting Information [Line Items]
Operating profit	$ 19.1	$ 16.4